Biopartnering Seminar Series - Can we Improve Patient Compliance for Simponi? (Janssen/Johnson & Johnson)

SCEMatix Team Photo
Tuesday, December 1, 2015 - 6:30pm
Can We Improve Patient Compliance for Simponi? (Janssen/Johnson & Johnson), SCEMatix - MBiotech Student Team

Tuesday, December 1, 2015, 6:30pm.
Room L1220, Innovation Complex.

Patient compliance is an important issue in healthcare. Failure to comply to treatment can result in poorer clinical outcomes, increased healthcare costs for patients, as well as decreased return for pharmaceutical companies. However, a significant portion of patients do not adhere to their prescribed medication, especially for treatments of chronic conditions. Janssen’s anti-TNFÉ‘ biologic drug, Simponi®, is self-administered subcutaneously and is indicated for moderate to severe rheumatoid arthritis, active ankylosing spondylitis, active psoriatic arthritis, and moderate to severe ulcerative colitis. Our team takes a patient-focused approach to reveal the underlying causes of non-compliance. 

 This project explores examples of compliance in and outside of healthcare to bring a new approach to tackle this long-standing issue. After discussions with key decision makers and individual patient interviews, we conducted a survey of 189 patients being treated for the indicated diseases. We analyzed reasons for non-compliance by age group and disease in order to tailor realistic solutions for these groups. Anxiety and forgetfulness were the most commonly reported reasons for non-compliance. In this presentation, we will examine the cost-effectiveness of different solutions that address these problems and ultimately enhance Janssen's BioAdvance patient support system. Potential solutions discussed will include gamification, patient-to-patient social support initiatives, and smart-reminder systems. Our innovative strategy aims to improve Janssen’s approach to patient compliance with Simponi®. 

This seminar will be open to the public.

This seminar is part of the Biopartnering Seminar Series, offered by the Master of Biotechnology Program.